A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives

Using the term of progressive multiple sclerosis (PMS), we considered a combined population of persons with secondary progressive MS (SPMS) and primary progressive MS (PPMS). These forms of MS cannot be challenged with efficacy by the licensed therapy. In the last years, several measures of risk est...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2016-10, Vol.17 (10), p.1725-1725
Main Authors: D'Amico, Emanuele, Patti, Francesco, Zanghì, Aurora, Zappia, Mario
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents - therapeutic use
Antioxidants - therapeutic use
Biomarkers - cerebrospinal fluid
future perspectives
Humans
Inflammation - pathology
Medical treatment
Mitochondria - pathology
Multiple sclerosis
Multiple Sclerosis, Chronic Progressive - drug therapy
Multiple Sclerosis, Chronic Progressive - pathology
Neuroprotective Agents - therapeutic use
Oxidative Stress
personalized treatment
Precision medicine
Precision Medicine - methods
Prognosis
progressive multiple sclerosis
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Using the term of progressive multiple sclerosis (PMS), we considered a combined population of persons with secondary progressive MS (SPMS) and primary progressive MS (PPMS). These forms of MS cannot be challenged with efficacy by the licensed therapy. In the last years, several measures of risk estimation were developed for predicting clinical course in MS, but none is specific for the PMS forms. Personalized medicine is a therapeutic approach, based on identifying what might be the best therapy for an individual patient, taking into account the risk profile. We need to achieve more accurate estimates of useful predictors in PMS, including unconventional and qualitative markers which are not yet currently available or practicable routine diagnostics. The evaluation of an individual patient is based on the profile of disease activity.Within the neurology field, PMS is one of the fastest-moving going into the future.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms17101725